CASI Pharmaceuticals, Inc. (CASI) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fortress Biotech, Inc.

Bolt Biotherapeutics, Inc.

Assembly Biosciences, Inc.

Sol-Gel Technologies Ltd.

CASI Pharmaceuticals, Inc.

SELLAS Life Sciences Group, Inc.

vTv Therapeutics, Inc.

Lantern Pharma, Inc.

Daré Bioscience, Inc.

NextCure, Inc.

Kineta, Inc.

Why is CASI Pharmaceuticals, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -2.32% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -34.69

Negative results in Jun 25

INTEREST(HY) At USD 0.44 MM has Grown at 701.82%
RAW MATERIAL COST(Y) Grown by 5.22% (YoY)
CASH AND EQV(HY) Lowest at USD 19.46 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -73.66%, its profits have fallen by -51.8%

Below par performance in long term as well as near term

Along with generating -73.66% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CASI Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

CASI Pharmaceuticals, Inc.

-72.6%

-0.58

110.65%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

25.49%

EBIT Growth (5y)

-2.32%

EBIT to Interest (avg)

-34.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.72

Sales to Capital Employed (avg)

-0.93

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

21.43%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-3.67

EV to EBIT

-0.88

EV to EBITDA

-0.88

EV to Capital Employed

-15.55

EV to Sales

1.13

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET SALES(HY)

At USD 10.41 MM has Grown at 40.97%

NET PROFIT(HY)

Higher at USD -23.97 MM

ROCE(HY)

Highest at 0%

DEBTORS TURNOVER RATIO(HY)

Highest at 4.82 times

-22What is not working for the Company

INTEREST(HY)

At USD 0.44 MM has Grown at 701.82%

RAW MATERIAL COST(Y)

Grown by 5.22% (YoY

CASH AND EQV(HY)

Lowest at USD 19.46 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -256.53 %

PRE-TAX PROFIT(Q)

Fallen at -28.17%

NET PROFIT(Q)

Lowest at USD -13.49 MM

Here's what is working for CASI Pharmaceuticals, Inc.

Net Sales

At USD 10.41 MM has Grown at 40.97%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 4.82 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for CASI Pharmaceuticals, Inc.

Interest

At USD 0.44 MM has Grown at 701.82%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit

At USD -13.49 MM has Fallen at -52.8%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit Margin

Lowest at -256.53 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Fallen at -28.17%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -13.49 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 19.46 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 5.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales